Breaking News

Immunogenicity of rituximab in patients with severe pemphigus

Immunogenicity of rituximab in patients with severe pemphigus

 
 

The development of anti-rituximab antibodies was determined in 11 pemphigus patients before and 3, 9 and 15 months after treatment with rituximab. In two patients, antibodies were detected and only a partial remission was obtained. Of nine patients without antibodies, all lesions healed in five, and partial remissions were seen in four. Antibodies to rituximab may thus be associated with a less than optimal outcome (Schmidt, E. et al. J Invest Dermatol 2009, 129 (Suppl. 2): 24, Abst 127).

 
to Continue Reading, Login Now
 

Please Login

 
 
  
 
 
If you are a registered user but you have forgotten your password, please click here
 
If you are not a registered user, please register here

return to breaking news list